Isabella Ciccone, MPH

September 27, 2022

In a randomized controlled trial, results demonstrated that acupuncture is to be efficacious in improving insomnia, quality of life, and affective symptoms for patients with ischemic stroke.

September 27, 2022

New Treatments for Duchenne Muscular Dystrophy: Emma Ciafaloni, MD The professor of Neurology and Pediatrics at University of Rochester Medical Center discusses the new and future treatments for Duchenne muscular dystrophy. [WATCH TIME: 4 minutes]

September 27, 2022

Results from pilot program using a VR-based platform suggest medical trainees may benefit from further VR training to gain a complete baseline knowledge of treating lower limb spasticity with onabotulinumtoxinA.

September 26, 2022

A nonrandomized pilot study demonstrated high adherence rates and acceptability ratings with tele-yoga breathing in patients with ALS, proving that it is a safe and feasible practice.

September 26, 2022

Adults with myasthenia gravis who contracted COVID-19 were at twice the risk of hospitalization, ICU admission, and death based on data from a recent population-based study.

September 25, 2022

In an investigation on the effect of treatment with efgartigimod on humoral immune responses to COVID-19 vaccination, the immunization resulted in antigen-specific IgG responses in most patients.

September 24, 2022

Findings from retrospective study show that repetitive nerve stimulation is a highly sensitive and specific test for the diagnosis of myasthenia gravis in an inpatient setting, with its results being more rapidly available in comparison with antibody testing.

September 23, 2022

Eplontersen treatment resulted in a significant reduction in transthyretin, neuropathy impairment, and improvement in quality of life in the phase 3 NEURO-TTRansform study of patients with hereditary transthyretin amyloidosis.

September 23, 2022

Investigators concluded that those receiving avalglucosidase alfa should be tested for antidrug antibodies by physicians who treat Pompe disease and monitor antidrug antibody, according to a recent Sanofi investigation.

September 22, 2022

ADAPT+ study data on antiacetylcholine receptor antibody-negative patients with generalized myasthenia gravis found improvements in cycle baseline and efficacy with Efgartigimod.